Peroxisome proliferator-activated receptor alpha and Peroxisome proliferator-activated receptor gamma (PPARα/γ)

Peroxisome proliferator-activated receptor alpha (PPAR-α) and peroxisome proliferator-activated receptor gamma (PPAR-γ) are members of the nuclear hormone receptor superfamily. They function as ligand-activated transcription factors that regulate genes involved in lipid and glucose metabolism, energy balance, inflammation, and adipocyte differentiation[1][2][3][4][5]. PPAR-α is highly expressed in tissues that oxidize fatty acids (such as liver and heart) and is essential for fatty acid catabolism, especially during fasting[2][3][4]. PPAR-γ is a master regulator of adipocyte differentiation and mediates insulin sensitivity and glucose metabolism[1][4][5]. Both receptors are therapeutic targets for metabolic disorders: PPAR-α agonists (fibrates) are used to lower triglyceride levels in dyslipidemia, while PPAR-γ agonists (thiazolidinediones) are used to improve insulin sensitivity in type 2 diabetes[1][2][4][5]. They also play roles in inflammatory and proliferative diseases, with emerging research into their utility for cancer, autoimmune conditions, and neurodegenerative disorders[4][5]. Safety concerns include fluid retention and heart failure risk (PPAR-γ agonists), weight gain, and possible hepatotoxicity[4][5]. PPARα/γ as a target refers to scenarios where dual agonists or ligands modulate both receptor subtypes, aiming to combine metabolic and anti-inflammatory benefits for treatment of complex metabolic diseases.

Other names

PPAR alpha/gammaNR1C1 (for PPAR-alpha)NR1C3 (for PPAR-gamma)PPARA (gene encoding PPAR-alpha)PPARG (gene encoding PPAR-gamma)

Ligand-activated transcription factor: drugs bind to the receptor and alter gene transcription of target genes involved in lipid and glucose metabolism[1][2][3]; Promotion of fatty acid uptake, utilization, catabolism, and β-oxidation (PPAR-α)[2][3][4]; Enhancement of insulin sensitivity, stimulation of glucose uptake, and adipogenesis (PPAR-γ)[1][4][5]; Suppression of inflammatory gene expression through transrepression (e.g., inhibition of NFκB, AP-1)[4][5]